SCHEMBL206966

SCHEMBL206966

CN(C)C1(Cc2cccc(Cl)c2)CCC(NC(=O)CCC(=O)NC2CCCCCCC2)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.62
THRB P10828 1/20 0.57
HPGD P15428 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.47
MAPT P10636 1/20 0.47
ALOX12 P18054 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
POLB P06746 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
EPHX1 P07099 2/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
KMT2A Q03164 1/20 0.45
ATM Q13315 1/20 0.44
GAA P10253 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206084 0.89 EPHX2 (0.47) EPHX2THRBHPGDMAPTNPC1
SCHEMBL205735 0.88 ALDH1A1 (0.55) EPHX2THRBHPGDMAPTNPC1
SCHEMBL206772 0.88 EPHX2 (0.47) EPHX2THRBHPGDMAPTALOX12
SCHEMBL206620 0.87 EPHX2 (0.46) EPHX2THRBHPGDMAPTALOX12
SCHEMBL4081016 0.86 EPHX2 (0.45) EPHX2THRBHPGDL3MBTL1SIGMAR1
SCHEMBL208454 0.86 ALDH1A1 (0.53) EPHX2THRBHPGDMAPTNPC1
SCHEMBL205653 0.86 SIGMAR1 (0.48) EPHX2THRBHPGDNPC1RAB9A
SCHEMBL2977995 0.86 THRB (0.48) EPHX2THRBHPGDL3MBTL1SIGMAR1
SCHEMBL206987 0.85 POLB (0.56) EPHX2THRBHPGDMAPTPOLB
SCHEMBL207581 0.85 POLB (0.46) EPHX2THRBHPGDMAPTALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
JP-2007536323-A 2007-12-13 JP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP claimed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed
EP-1745010-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2007-01-24 EP disclosed
WO-2005110974-A1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES Grünenthal GmbH (DE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD EPHX2 1203/4885THRB 4068/4885HPGD 96/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.